Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 12/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 3/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15311000 | 0.99 | PARP1 (0.41) | SCN10AKCNH2PARP1HCRTR1HCRTR2 | |
| SCHEMBL15311225 | 0.97 | SCN10A (0.40) | SCN10AKCNH2PARP1HCRTR1HCRTR2 | |
| SCHEMBL15311010 | 0.83 | SCN10A (0.38) | SCN10AKCNH2HCRTR1HCRTR2KIF11 | |
| SCHEMBL15310967 | 0.83 | PARP1 (0.44) | SCN10AKCNH2PARP1KIF11HDAC6 | |
| SCHEMBL5104085 | 0.77 | PARP1 (0.44) | PARP1HCRTR1HCRTR2HRH4HRH3 | |
| SCHEMBL5100661 | 0.75 | PARP1 (0.43) | PARP1HCRTR1HCRTR2HRH4HRH3 | |
| SCHEMBL13619366 | 0.72 | FABP6 (0.50) | SCN10AKCNH2KIF11HDAC6HRH4 | |
| SCHEMBL5104031 | 0.72 | HRH4 (0.41) | PARP1HRH4 | |
| SCHEMBL15311013 | 0.71 | PARP1 (0.41) | PARP1HDAC6 | |
| SCHEMBL1173774 | 0.71 | PARP1 (0.45) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2809655-B1 | BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8927587-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20130274243-A1 | Chemical Compounds | PFIZER LTD (GB) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274243-A1 | Chemical Compounds | SCN8A, SCN5A, KCNJ8 | SCN10A 51/4885KCNH2 7/4885PARP1 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.